July 29 (Reuters) – Johnson & Johnson cut 2026 profit forecast on Wednesday, citing the combined financial impact of its newly completed acquisition of Firefly Bio and a strategic partnership with Sail Biomedicines.
The healthcare giant expects full-year adjusted earnings per share of $10.96 to $11.11, compared with its previous forecast of $11.60 to $11.75. Its shares were down 1.4% in extended trading.
The two transactions are expected to reduce the company’s 2026 adjusted earnings by about $0.64 per share, with the Firefly acquisition contributing $0.46 and the Sail Biomedicines agreement $0.18.
The maker of drugs and medical devices, however, kept its annual revenue expectations intact at $100.8 billion to $101.4 billion.
Johnson & Johnson also said the Sail and Firefly deals were expected to impact 2027 adjusted earnings by $1.36 per share, comprising $0.08 from Firefly and $1.28 from Sail, contingent on the achievement of specified development milestones and the exercise of its contractual options.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar)
